Momelotinib
Medication
From Wikipedia, the free encyclopedia
Momelotinib, sold under the brand name Ojjaara among others, is an anticancer medication used for the treatment of myelofibrosis.[5] It is a Janus kinase inhibitor and it is taken by mouth.[5]
| |
| Names | |
|---|---|
| Preferred IUPAC name
N-(Cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide | |
Other names
| |
| Identifiers | |
| |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank |
|
| KEGG | |
PubChem CID |
|
| UNII |
|
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C23H22N6O2 | |
| Molar mass | 414.469 g·mol−1 |
| Pharmacology | |
| L01EJ04 (WHO) | |
| By mouth | |
| Legal status | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
| Clinical data | |
|---|---|
| Other names | Momelotinib hydrochloride hydrate (JAN JP), Momelotinib dihydrochloride (USAN US) |
| License data |
|
| Identifiers | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
The most common adverse reactions include dizziness, fatigue, bacterial infection, hemorrhage, thrombocytopenia, diarrhea, and nausea.[8]
Momelotinib was approved for medical use in the United States in September 2023,[5][8][9] and in the European Union in January 2024.[6][10]
Medical uses
Pharmacology
Society and culture
Legal status
In November 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Omjjara, intended for the treatment of disease-related splenomegaly or symptoms in adults with moderate-to-severe anemia who have primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.[12] The applicant for this medicinal product is Glaxosmithkline Trading Services Limited.[12] Momelotinib was approved for medical use in the European Union in January 2024.[6][7]
